News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Argenica flies over 15pc after FDA grants Rare Pediatric Disease Designation
Health & Biotech
LTR Pharma commences dosing for pivotal erectile dysfunction study of SPONTAN
Health & Biotech
ASX stocks striving to inject youthfulness into an aging world population
News
Closing Bell: Local markets ride commodities higher after a blow to US confidence on Friday
Health & Biotech
ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc
Health & Biotech
LTR Pharma firms up study for erectile dysfunction with patient recruitment
News
ASX Small Caps Lunch Wrap: Is this the weaponised AI we’re supposed to be scared of?
Health & Biotech
ASX Health Stocks: LTP is recruiting for patients to try its erection spray
News
ASX Quarterly Wrap: LTR Pharma firms up, Wisr expands margins and revenue growth
IPO Watch
Raised and risen: LTR Pharma floated to top of Aussie IPO pool in 2023, ahead of LU7
IPO Watch
IPO Wrap: Hot IPOs in 2024 from around the world; and a look at the final 2023 scorecard for ASX
News
ASX Small Caps and IPO Weekly Wrap: A Benchmark bonanza, but harder to pick than a broken nose
News
